Cargando…

PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model

While chimeric antigen receptor (CAR) T cell immunotherapy targeting CD19 has shown remarkable success in patients with lymphoid malignancies, the potency of CAR T cells in solid tumors is low so far. To improve the efficacy of CAR T cells targeting prostate carcinoma, we designed a novel CAR that r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alzubi, Jamal, Dettmer-Monaco, Viviane, Kuehle, Johannes, Thorausch, Niko, Seidl, Maximilian, Taromi, Sanaz, Schamel, Wolfgang, Zeiser, Robert, Abken, Hinrich, Cathomen, Toni, Wolf, Philipp
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372156/ https://www.ncbi.nlm.nih.gov/pubmed/32728611 http://dx.doi.org/10.1016/j.omto.2020.06.014

Ejemplares similares

An Anti-PSMA Immunotoxin Reduces Mcl-1 and Bcl2A1 and Specifically Induces in Combination with the BAD-Like BH3 Mimetic ABT-737 Apoptosis in Prostate Cancer Cells
por: Masilamani, Anie P., et al.
Publicado: (2020)

Non-integrating gamma-retroviral vectors as a versatile tool for transient zinc-finger nuclease delivery
por: Bobis-Wozowicz, Sylwia, et al.
Publicado: (2014)

CAR T Cells: A Snapshot on the Growing Options to Design a CAR
por: Holzinger, Astrid, et al.
Publicado: (2019)

Targeted multi-epitope switching enables straightforward positive/negative selection of CAR T cells
por: Mosti, Laura, et al.
Publicado: (2021)

CAR T cell therapy becomes CHIC: “cytokine help intensified CAR” T cells
por: Thomas, Simone, et al.
Publicado: (2023)

CAR's made it to the pancreas
por: Chmielewski, Markus, et al.
Publicado: (2012)

A Small Number of HER2 Redirected CAR T Cells Significantly Improves Immune Response of Adoptively Transferred Mouse Lymphocytes against Human Breast Cancer Xenografts
por: Tóth, Gábor, et al.
Publicado: (2020)

Do Treg Speed Up with CARs? Chimeric Antigen Receptor Treg Engineered to Induce Transplant Tolerance
por: Kaljanac, Marcell, et al.
Publicado: (2022)

FimH-based display of functional eukaryotic proteins on bacteria surfaces
por: Chmielewski, Markus, et al.
Publicado: (2019)

Enhanced cytotoxicity of a Pseudomonas Exotoxin A based immunotoxin against prostate cancer by addition of the endosomal escape enhancer SO1861
por: Masilamani, Anie P., et al.
Publicado: (2023)

Adoptive T cell therapy cures mice from active hemophagocytic lymphohistiocytosis (HLH)
por: Weißert, Kristoffer, et al.
Publicado: (2022)

Most Do, but Some Do Not: CD4(+)CD25(−) T Cells, but Not CD4(+)CD25(+) Treg Cells, Are Cytolytic When Redirected by a Chimeric Antigen Receptor (CAR)
por: Hombach, Andreas A., et al.
Publicado: (2017)

TALE-PvuII Fusion Proteins – Novel Tools for Gene Targeting
por: Yanik, Mert, et al.
Publicado: (2013)

Ex Vivo Generation of CAR Macrophages from Hematopoietic Stem and Progenitor Cells for Use in Cancer Therapy
por: Paasch, Daniela, et al.
Publicado: (2022)

IRF4 downregulation improves sensitivity and endurance of CAR T cell functional capacities
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

Automated generation of gene-edited CAR T cells at clinical scale
por: Alzubi, Jamal, et al.
Publicado: (2020)

Rescue of DNA-PK Signaling and T-Cell Differentiation by Targeted Genome Editing in a prkdc Deficient iPSC Disease Model
por: Rahman, Shamim H., et al.
Publicado: (2015)

Nanobody Based Dual Specific CARs
por: De Munter, Stijn, et al.
Publicado: (2018)

Targeted genome editing restores T cell differentiation in a humanized X-SCID pluripotent stem cell disease model
por: Alzubi, Jamal, et al.
Publicado: (2017)

Generation of an NFκB-Driven Alpharetroviral “All-in-One” Vector Construct as a Potent Tool for CAR NK Cell Therapy
por: Rudek, Loreen Sophie, et al.
Publicado: (2021)

Transcriptomic Landscape and Functional Characterization of Human Induced Pluripotent Stem Cell-Derived Limbal Epithelial Progenitor Cells
por: Polisetti, Naresh, et al.
Publicado: (2022)

CAR Triggered Release of Type-1 Interferon Limits CAR T-Cell Activities by an Artificial Negative Autocrine Loop
por: Harrer, Dennis Christoph, et al.
Publicado: (2022)

Harnessing CD3 diversity to optimize CAR T cells
por: Velasco Cárdenas, Rubí M.-H., et al.
Publicado: (2023)

Design and Characterization of an “All-in-One” Lentiviral Vector System Combining Constitutive Anti-G(D2) CAR Expression and Inducible Cytokines
por: Zimmermann, Katharina, et al.
Publicado: (2020)

IL7-IL12 Engineered Mesenchymal Stem Cells (MSCs) Improve A CAR T Cell Attack Against Colorectal Cancer Cells
por: Hombach, Andreas A., et al.
Publicado: (2020)

CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process
por: Altvater, Bianca, et al.
Publicado: (2023)

A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2(+) Solid Cancer
por: Hombach, Andreas A., et al.
Publicado: (2023)

Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells
por: Harrer, Dennis Christoph, et al.
Publicado: (2022)

Building on Synthetic Immunology and T Cell Engineering: A Brief Journey Through the History of Chimeric Antigen Receptors
por: Abken, Hinrich
Publicado: (2021)

TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity
por: Mussolino, Claudio, et al.
Publicado: (2014)

Cell-Based Models of ‘Cytokine Release Syndrome’ Endorse CD40L and Granulocyte–Macrophage Colony-Stimulating Factor Knockout in Chimeric Antigen Receptor T Cells as Mitigation Strategy
por: Dibas, Ala, et al.
Publicado: (2023)

S80. Prolongation of T cell response by OX40 co-signalling CARS
por: Abken, H
Publicado: (2014)

IL12 integrated into the CAR exodomain converts CD8(+) T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors
por: Hombach, Andreas, et al.
Publicado: (2022)

P1354: CRISPR/CAS9 GENE EDITING OF IMMUNE CHECKPOINT RECEPTOR NKG2A IMPROVES THE ANTI-LEUKEMIC EFFICACY OF PRIMARY CD33-TARGETING CAR-NK CELLS.
por: Albinger, Nawid, et al.
Publicado: (2023)

Imaging CAR T cell therapy with PSMA-targeted positron emission tomography
por: Minn, Il, et al.
Publicado: (2019)

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer
por: Zarrabi, Kevin K., et al.
Publicado: (2023)

CXCR4 antagonists suppress small cell lung cancer progression
por: Taromi, Sanaz, et al.
Publicado: (2016)

Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia
por: El Khawanky, Nadia, et al.
Publicado: (2021)

The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth
por: Schmidt, Patrick, et al.
Publicado: (2011)

Chimeric antigen receptors designed to overcome transforming growth factor‐β‐mediated repression in the adoptive T‐cell therapy of solid tumors
por: Hartley, Jordan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jal6ka3m8tcpqs2mhj9h7pd6mc